Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
Joachim H IxTamara IsakovaBrett LariveKalani L RaphaelDominic S RajAlfred K CheungStuart M SpragueLinda F FriedJennifer J GassmanJohn P MiddletonMichael F FlessnerGeoffrey A BlockMyles WolfPublished in: Journal of the American Society of Nephrology : JASN (2019)
LC and/or NAM treatment did not significantly lower serum phosphate or FGF23 in stage 3b/4 CKD over 12 months. Although these agents appeared safe, intestinal symptoms limited adherence. Reducing phosphate and FGF23 in nondialysis CKD will require new approaches.